List of Xpovio drug patents

Xpovio is owned by Karyopharm Theraps.

Xpovio contains Selinexor.

Xpovio has a total of 6 drug patents out of which 0 drug patents have expired.

Xpovio was authorised for market use on 03 July, 2019.

Xpovio is available in tablet;oral dosage forms.

Xpovio can be used as xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Drug patent challenges can be filed against Xpovio from July, 2023.

The generics of Xpovio are possible to be released after 14 August, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9714226 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US8999996 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Sep, 2032

(9 years from now)

US10519139 KARYOPHARM THERAPS Polymorphs of Selinexor
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079865 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US10544108 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US11034660 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2027
New Chemical Entity Exclusivity (NCE) Jul 3, 2024
New Indication (I) Jun 22, 2023

Drugs and Companies using SELINEXOR ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 03 July, 2019

Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; Xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic